<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>2</IssueIDStart>
          <IssueIDEnd>2</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>6</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art22">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>72467</ArticleID>
            <ArticleDOI>10.1208/aapsj070247</ArticleDOI>
            <ArticleSequenceNumber>22</ArticleSequenceNumber>
            <ArticleTitle Language="En">Evidence of effectiveness: How much can we extrapolate from existing studies?</ArticleTitle>
            <ArticleFirstPage>E467</ArticleFirstPage>
            <ArticleLastPage>E474</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>23</Day>
              </RegistrationDate>
              <Received>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>3</Day>
              </Received>
              <Accepted>
                <Year>2005</Year>
                <Month>5</Month>
                <Day>4</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>2</IssueIDStart>
              <IssueIDEnd>2</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" CorrespondingAffiliationID="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Howard</GivenName>
                  <FamilyName>Lee</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(412) 624-9485</Phone>
                  <Fax>(412) 648-7107</Fax>
                  <Email>leehwd@yahoo.com</Email>
                </Contact>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Dong-Seok</GivenName>
                  <FamilyName>Yim</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Honghui</GivenName>
                  <FamilyName>Zhou</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Carl</GivenName>
                  <GivenName>C.</GivenName>
                  <FamilyName>Peck</FamilyName>
                </AuthorName>
              </Author>
              <Affiliation ID="Aff1">
                <OrgDivision>Center for Clinical Pharmacology</OrgDivision>
                <OrgName>University of Pittsburgh</OrgName>
                <OrgAddress>
                  <Postcode>15219</Postcode>
                  <City>Pittsburgh</City>
                  <State>PA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgDivision>Center for Drug Development Science</OrgDivision>
                <OrgName>Washington DC Center</OrgName>
                <OrgAddress>
                  <Postcode>20036</Postcode>
                  <City>Washington, DC</City>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgDivision>Clinical Pharmacology and Experimental Medicine</OrgDivision>
                <OrgName>Centocor Inc, Johnson &amp; Johnson</OrgName>
                <OrgAddress>
                  <Postcode>19087</Postcode>
                  <City>Radnor</City>
                  <State>PA</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>Drug development can be a science of extrapolation if the use of a drug exposure-response relationship is embraced and implemented through mechanistically oriented pharmacokinetic (PK)-pharmacodynamic (PD) modeling analysis and clinical trial simulation. The traditional requirement of at least 2 adequate and well-controlled phase III studies by the US Food and Drug Administration for drug approval can be waived in certain situations, substantially reducing the resources and time. In this article, the authors introduce a real drug development case where the chance for this exemption was maximized by actively using PK-PD modeling followed by clinical trial simulation, resulting in faster and more economical introduction of a new dosage regimen to patients.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>extrapolation</Keyword>
              <Keyword>drug development science</Keyword>
              <Keyword>pharmacokinetic-pharmacodynamic modeling</Keyword>
              <Keyword>exposure-response relationship</Keyword>
              <Keyword>etanercept</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: October 5, 2005</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_72467.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Sheiner</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Steimer</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Pharmacokinetic/pharmacodynamic modeling in drug development</ArticleTitle>
                  <JournalTitle>Annu Rev Pharmacol Toxicol</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>67</FirstPage>
                  <LastPage>95</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10836128</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1146/annurev.pharmtox.40.1.67</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXjs1yhsrg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sheiner LB, Steimer JL. Pharmacokinetic/pharmacodynamic modeling in drug development.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:67–95.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry</InstitutionalAuthorName>
                  <Year>2003</Year>
                  <BookTitle>Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications</BookTitle>
                  <PublisherName>Food and Drug Administration</PublisherName>
                  <PublisherLocation>Rockville, MD</PublisherLocation>
                </BibBook>
                <BibUnstructured>Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry.<Emphasis Type="Italic">Exposure-Response Relationships—Study Design, Data Analysis, and Regulatory Applications</Emphasis>. Rockville, MD: Food and Drug Administration, 2003.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Sheiner</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Learning versus confirming in clinical drug development</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>61</VolumeID>
                  <FirstPage>275</FirstPage>
                  <LastPage>291</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9084453</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0009-9236(97)90160-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:ByiB3sfhtFM%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Sheiner LB. Learning versus confirming in clinical drug development.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 1997;61:275–291.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibBook>
                  <InstitutionalAuthorName>Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry</InstitutionalAuthorName>
                  <Year>1999</Year>
                  <BookTitle>Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products</BookTitle>
                  <PublisherName>Food and Drug Administration</PublisherName>
                  <PublisherLocation>Rockville, MD</PublisherLocation>
                </BibBook>
                <BibUnstructured>Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration. Guidance for Industry.<Emphasis Type="Italic">Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products</Emphasis>. Rockville, MD: Food and Drug Administration, 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibUnstructured>The US Congress. The Federal Food, Drug, and Cosmetic Act, as amended in 1962. Pub. L. No. 87-781, 76 Stat. 780. 1962.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibUnstructured>The US Congress. The Food and Drug Administration Modernization Act of 1997. Pub. L. No. 105-115, 111 Stat. 2295. 1997.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Peck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DB</Initials>
                    <FamilyName>Rubin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Sheiner</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>73</VolumeID>
                  <FirstPage>481</FirstPage>
                  <LastPage>490</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12811358</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0009-9236(03)00018-3</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Peck CC, Rubin DB, Sheiner LB. Hypothesis: a single clinical trial plus causal evidence of effectiveness is sufficient for drug approval.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2003;73:481–490.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SK</Initials>
                    <FamilyName>Dower</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CA</Initials>
                    <FamilyName>Smith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LS</Initials>
                    <FamilyName>Park</FamilyName>
                  </BibAuthorName>
                  <Year>1990</Year>
                  <ArticleTitle Language="En">Human cytokine receptors</ArticleTitle>
                  <JournalTitle>J Clin Immunol</JournalTitle>
                  <VolumeID>10</VolumeID>
                  <FirstPage>289</FirstPage>
                  <LastPage>299</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1964693</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/BF00917473</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK3MXmt12ltbk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dower SK, Smith CA, Park LS. Human cytokine receptors.<Emphasis Type="Italic">J Clin Immunol</Emphasis>. 1990;10:289–299.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LW</Initials>
                    <FamilyName>Moreland</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SB</Initials>
                    <FamilyName>Cohen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SW</Initials>
                    <FamilyName>Baumgartner</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis</ArticleTitle>
                  <JournalTitle>J Rheumatol</JournalTitle>
                  <VolumeID>28</VolumeID>
                  <FirstPage>1238</FirstPage>
                  <LastPage>1244</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11409115</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXkvVOhu7g%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis.<Emphasis Type="Italic">J Rheumatol</Emphasis>. 2001;28:1238–1244.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Bathon</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RW</Initials>
                    <FamilyName>Martin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RM</Initials>
                    <FamilyName>Fleischmann</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis</ArticleTitle>
                  <JournalTitle>N Engl J Med</JournalTitle>
                  <VolumeID>343</VolumeID>
                  <FirstPage>1586</FirstPage>
                  <LastPage>1593</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11096165</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1056/NEJM200011303432201</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXovVeltLg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.<Emphasis Type="Italic">N Engl J Med</Emphasis>. 2000;343:1586–1593.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibUnstructured>Label for Enbrel<Superscript>®</Superscript> (etanercept). 2004.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Korth-Bradley</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>AS</Initials>
                    <FamilyName>Rubin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RK</Initials>
                    <FamilyName>Hanna</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DK</Initials>
                    <FamilyName>Simcoe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Lebsack</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">The pharmacokinetics of etanercept in healthy volunteers</ArticleTitle>
                  <JournalTitle>Ann Pharmacother</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>161</FirstPage>
                  <LastPage>164</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10676822</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1345/aph.19126</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXht1arsrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Korth-Bradley JM, Rubin AS, Hanna RK, Simcoe DK, Lebsack ME. The pharmacokinetics of etanercept in healthy volunteers.<Emphasis Type="Italic">Ann Pharmacother</Emphasis>. 2000;34:161–164.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>ME</Initials>
                    <FamilyName>Lebsack</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RK</Initials>
                    <FamilyName>Hanna</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Lange</FamilyName>
                  </BibAuthorName>
                  <Year>1997</Year>
                  <ArticleTitle Language="En">Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers</ArticleTitle>
                  <JournalTitle>Pharmacotherapy</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>1181</FirstPage>
                  <LastPage>1189</LastPage>
                </BibArticle>
                <BibUnstructured>Lebsack ME, Hanna RK, Lange MA. Absolute bioavailability of TNF receptor fusion protein following subcutaneous injection in healthy volunteers.<Emphasis Type="Italic">Pharmacotherapy</Emphasis>. 1997;17:1181–1189.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Kimko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Rogge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Nestorov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Peck</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>73</VolumeID>
                  <FirstPage>348</FirstPage>
                  <LastPage>365</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12709725</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0009-9236(02)17635-1</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjtFWntb0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2003;73:348–365.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibUnstructured>Immunex. Data on File, Etanercept. 1999.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PL</Initials>
                    <FamilyName>Bonate</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Clinical trial simulation in drug development</ArticleTitle>
                  <JournalTitle>Pharm Res</JournalTitle>
                  <VolumeID>17</VolumeID>
                  <FirstPage>252</FirstPage>
                  <LastPage>256</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10801212</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1023/A:1007548719885</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXivVKls7k%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bonate PL. Clinical trial simulation in drug development.<Emphasis Type="Italic">Pharm Res</Emphasis>. 2000;17:252–256.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Kimko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SS</Initials>
                    <FamilyName>Reele</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>NH</Initials>
                    <FamilyName>Holford</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Peck</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>68</VolumeID>
                  <FirstPage>568</FirstPage>
                  <LastPage>577</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11103759</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1067/mcp.2000.110975</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXovVeru7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kimko HC, Reele SS, Holford NH, Peck CC. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2000;68:568–577.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HC</Initials>
                    <FamilyName>Kimko</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Rogge</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>D</Initials>
                    <FamilyName>Wang</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Nestorov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Peck</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">50 mg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time-concentration profile with 25 mg twice weekly dosing</ArticleTitle>
                  <JournalTitle>Clin Pharmacol Ther</JournalTitle>
                  <VolumeID>71</VolumeID>
                  <FirstPage>90</FirstPage>
                  <LastPage>90</LastPage>
                </BibArticle>
                <BibUnstructured>Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. 50 mg once weekly subcutaneous regimen of etanercept will yield an overlapping steady state time-concentration profile with 25 mg twice weekly dosing.<Emphasis Type="Italic">Clin Pharmacol Ther</Emphasis>. 2002;71:90.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EC</Initials>
                    <FamilyName>Keystone</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MH</Initials>
                    <FamilyName>Schiff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Kremer</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial</ArticleTitle>
                  <JournalTitle>Arthritis Rheum</JournalTitle>
                  <VolumeID>50</VolumeID>
                  <FirstPage>353</FirstPage>
                  <LastPage>363</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14872476</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/art.20019</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhvFeitLc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.<Emphasis Type="Italic">Arthritis Rheum</Emphasis>. 2004;50:353–363.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DS</Initials>
                    <FamilyName>Yim</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Zhou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Buckwalter</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>I</Initials>
                    <FamilyName>Nestorov</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CC</Initials>
                    <FamilyName>Peck</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Lee</FamilyName>
                  </BibAuthorName>
                  <Year>2005</Year>
                  <ArticleTitle Language="En">Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis</ArticleTitle>
                  <JournalTitle>J Clin Pharmacol</JournalTitle>
                  <VolumeID>45</VolumeID>
                  <FirstPage>246</FirstPage>
                  <LastPage>256</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15703360</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1177/0091270004271945</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXks1SlsLk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yim DS, Zhou H, Buckwalter M, Nestorov I, Peck CC Lee H. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis.<Emphasis Type="Italic">J Clin Pharmacol</Emphasis>. 2005;45:246–256.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibUnstructured>Amgen. FDA approves enbrel for once-weekly dosing: new dosing option offers convenience to patients while providing comparable efficacy and tolerability. Amgen press release. October 23, 2003.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
